{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:09:49Z","timestamp":1778944189726,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,17]],"date-time":"2015-09-17T00:00:00Z","timestamp":1442448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12902-015-0045-y","type":"journal-article","created":{"date-parts":[[2015,9,17]],"date-time":"2015-09-17T16:01:45Z","timestamp":1442505705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database"],"prefix":"10.1186","volume":"15","author":[{"given":"Makito","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nomiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Motonaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunitaka","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Yanase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,17]]},"reference":[{"key":"45_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2337\/diacare.22.5.756","volume":"22","author":"R Marco de","year":"1999","unstructured":"de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756\u201361.","journal-title":"Diabetes Care"},{"key":"45_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"S Haffner","year":"1998","unstructured":"Haffner S, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229\u201334.","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"45_CR3","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/diab.45.3.S14","volume":"45","author":"M Fujishima","year":"1996","unstructured":"Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes. 1996;45 Suppl 3:S14\u20136.","journal-title":"Diabetes"},{"key":"45_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2337\/diacare.24.8.1422","volume":"24","author":"KJ Mukamal","year":"2001","unstructured":"Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care. 2001;24:1422\u20137.","journal-title":"Diabetes Care"},{"key":"45_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","volume":"157","author":"CL Roumie","year":"2012","unstructured":"Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601\u201310.","journal-title":"Ann Intern Med"},{"key":"45_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","volume":"147","author":"S Bolen","year":"2007","unstructured":"Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386\u201399.","journal-title":"Ann Intern Med"},{"key":"45_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"JL Chiasson","year":"2003","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486\u201394.","journal-title":"JAMA"},{"key":"45_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","volume":"25","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. European Heart J. 2004;25:10\u20136.","journal-title":"European Heart J"},{"key":"45_CR9","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino Sr RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572\u201381.","journal-title":"JAMA"},{"key":"45_CR10","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA. 2008;299:1561\u201373.","journal-title":"JAMA"},{"key":"45_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"JR Ussher","year":"2012","unstructured":"Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187\u2013215.","journal-title":"Endocr Rev"},{"key":"45_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"45_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"45_CR14","doi-asserted-by":"crossref","unstructured":"Tajima M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, et al. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetol Int. 2015; doi: 10.1007\/s13340-015-0206-2","DOI":"10.1007\/s13340-015-0206-2"},{"key":"45_CR15","first-page":"145","volume":"29","author":"T Yanase","year":"2011","unstructured":"Yanase T, Takenoshita H, Murase K, Nagaishi R, Nomiyama T, Akehi Y. Utility study of a basic database collected from patients with diabetes mellitus in 15 hospitals by retrospective analysis. Pharma Medica. 2011;29:145\u201352. In Japanese, abstract in English.","journal-title":"Pharma Medica"},{"key":"45_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053224","volume":"7","author":"H Urushihara","year":"2012","unstructured":"Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS One. 2012;7, e53224.","journal-title":"PLoS One"},{"key":"45_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","volume":"13","author":"C Lamanna","year":"2011","unstructured":"Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13:221\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2337\/diacare.16.7.1035","volume":"16","author":"JC Chan","year":"1993","unstructured":"Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 1993;16:1035\u20138.","journal-title":"Diabetes Care"},{"key":"45_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2337\/diacare.16.4.621","volume":"16","author":"DK Nagi","year":"1993","unstructured":"Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16:621\u20139.","journal-title":"Diabetes Care"},{"key":"45_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10557-012-6425-x","volume":"27","author":"HJ Whittington","year":"2013","unstructured":"Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27:5\u201316.","journal-title":"Cardiovasc Drugs Ther"},{"key":"45_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/heart.90.1.9","volume":"90","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA. Is impairment of ischemic preconditioning by sulfonylurea drugs clinically important? Heart. 2004;90:9\u201312.","journal-title":"Heart"},{"key":"45_CR22","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"45_CR23","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","unstructured":"ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"45_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339.","journal-title":"N Engl J Med"},{"issue":"Suppl.2","key":"45_CR25","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc11-s220","volume":"34","author":"BM Frier","year":"2011","unstructured":"Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34(Suppl2):S132\u2013137.","journal-title":"Diabetes Care"},{"key":"45_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"45_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-014-0154-3","volume":"13","author":"Y Terawaki","year":"2014","unstructured":"Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014;13:154.","journal-title":"Cardiovasc Diabetol"},{"key":"45_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1210\/en.2012-1855","volume":"154","author":"N Ervinna","year":"2013","unstructured":"Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013;154:1260\u201370.","journal-title":"Endocrinology"},{"key":"45_CR29","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.diabres.2011.08.016","volume":"95","author":"T Nomiyama","year":"2012","unstructured":"Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e27\u201328.","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl.1","key":"45_CR30","first-page":"S11","volume":"35","author":"American Diabetes Association","year":"2012","unstructured":"American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care. 2012;35(Suppl1):S11\u201363.","journal-title":"Diabetes Care"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-015-0045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-015-0045-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-015-0045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T19:43:51Z","timestamp":1498247031000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-015-0045-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1186\/s12902-015-0045-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,17]]},"article-number":"49"}}